Intravenous immunoglobulin-induced hemolytic anemia in a patient with juvenile dermatomyositis

Journal of Drugs in Dermatology

Volumn 12, Issue 1, 2013, Pages 111-113

  Clemenz, Melanie R ^a   Joseph Wilson McGowan, ^a   Shuler, Marshall J ^a   Lynn, Annette W ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BILIRUBIN; CREATINE KINASE; HAPTOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; PREDNISONE;

ARTICLE; BLOOD SMEAR; CASE REPORT; CHILD; COOMBS TEST; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; ERYTHROCYTE; ERYTHROCYTE DISORDER; FEMALE; FEVER; GAMMOPATHY; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; JUVENILE DERMATOMYOSITIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYALGIA; PROTEIN BLOOD LEVEL; RETICULOCYTE COUNT; SCHOOL CHILD; THROMBOCYTE COUNT; TREATMENT DURATION;

ANEMIA, HEMOLYTIC; BIOPSY; CHILD; DERMATOMYOSITIS; ERYTHROCYTE COUNT; FEMALE; HAPTOGLOBINS; HEMOGLOBINS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MUSCULOSKELETAL PAIN; SKIN;

EID: 84873471515     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Latov N, Chaudhry V, Koski CL, et al. Use of intravenous gamma globulins in neuroimmunologic diseases. J Allergy Clin Immunol. 2001;108(4 Suppl):S126-S132.
2. Peloro TM, Miller OF 3rd, Hahn TF, Newman ED. Juvenile dermatomyositis: a retrospective review of a 30-year experience. J Am Acad Dermatol. 2001;45(1):28-34.
3. Sullivan DB, Cassidy JT, Petty RE. Dermatomyositis in the pediatric patient. Arthritis Rheum. 1977;20(2 Suppl):327-331.
4. Pachman LM. Juvenile dermatomyositis. Pathology and disease expression. Pediatr Clin North Am. 1995;42(5):1071-1098.
5. Pachman LM. Polymyositis and dermatomyositis in children. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology. Oxford, UK: Oxford University Press; 1993:821-828.
6. Oddis CV. Idiopathic inflammatory myopathy: management and prognosis. Rheum Dis Clin North Am. 2002;28(4):979-1001.
7. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993-2000.
8. Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology. 2001;62(3):133-137.
9. Miyagi F, Horiuchi H, Nagata I, et al. Fc portion of intravenous immunoglobulins suppresses the induction of experimental allergic neuritis. J Neuroimmunol. 1997;78(1-2):127-131.
10. Sharief MK, Ingram DA, Swash M, Thompson EJ. I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology. 1999;52(9):1833-1838.
11. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94(5):1729-1735.
12. Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol. 1996;104 suppl 1:21-25.
13. Wilson JR, Bhoopalam H, Fisher M. Hemolytic anemia associated with intravenous immunoglobulin. Muscle Nerve. 1997;20(9):1142-1145.
14. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica. 1993;78(6 Suppl 2):35-40.
15. Trifa M, Simon L, Hamza J, Bavoux F, des Roziers NB. Haemolytic anaemia associated with high dose intravenous immunoglobulin therapy in a child with Guillain-Barré syndrome. Arch Dis Child. 2003;88(9):836-837.
16. Nakagawa M, Watanabe N, Okuno M, Kondo M, Okagawa H, Taga T. Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease. Am J Hematol. 2000;63(3):160-161.
17. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. 1991;77(9):1884-1893.
18. Turner CE, Thorpe SJ, Brasher MD, Thorpe R. Anti-Rh D activity of commercial intravenous immunoglobulin preparations. Vox Sang. 1999;76(1):55-58.
19. Zipursky A, Bowman JM. Isoimmune hemolytic diseases. In: Nathan DJ, Oski FA, eds. Hematology of Infancy and Childhood. 4th ed. Philadelphia, PA: W.B. Saunders; 1993:44-74.
20. Ballot-Brossier C, Mortelecque R, Sinègre M, Marceau A, Dauriat G, Courtois F. Insisting on intravenous polyvalent immunoglobulin therapy in polymyositis in spite of the occurrence of severe hemolytic anemia [in French]. Transfus Clin Biol. 2001;8(2):94-99.
21. Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2000;95(8):2523-2529.
22. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology. 2002;59(12 Suppl 6):S28-S32.
23. Okubo S, Yasunaga K, Ishida T. Studies of IgG subclasses of anti-erythrocyte antibodies contained in human plasma preparation products [in Japanese]. Rinsho Ketsueki. 1989;30(3):323-326.
24. Shoham-Kessary H, Naot Y, Gershon H. Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes. Clin Exp Immunol. 1998;113(1):77-84.
25. Wang Z, Shi J, Zhou Y, Ruan C. Detection of red blood cell-bound immunoglobulin G by flow cytometry and its application in the diagnosis of autoimmune hemolytic anemia. Int J Hematol. 2001;73(2):188-193.
26. Shoham-Kessary H, Gershon H. Isoantibodies in immunoglobulin for intravenous use may cause erythrocyte sequestration. Vox Sang. 1999;77(1):33-39.